Gefitinib Tablets (Unigef) 250 MG

Gefitinib tablets IP 250 mg is a medication primarily used to treat non-small cell lung cancer (NSCLC) that has specific genetic mutations. Here's a concise description with pointers:

1. Purpose: Gefitinib is indicated for the treatment of non-small cell lung cancer (NSCLC) that has specific epidermal growth factor receptor (EGFR) mutations.

2. Administration: Administered orally as tablets, usually taken once daily with or without food.

3. Mechanism of Action: Gefitinib inhibits the activity of EGFR tyrosine kinase, blocking the signals that promote cancer cell growth and proliferation.

4. Indications: Used for the first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

5. Dosage: The standard dosage is 250 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

6. Side Effects: Common side effects may include diarrhea, rash, acne, nausea, and fatigue. Serious adverse reactions such as interstitial lung disease or liver toxicity may occur.

7. Contraindications: Avoid use in patients with a known hypersensitivity to gefitinib or any components of the formulation.

8. Precautions: Gefitinib should be used cautiously in patients with a history of liver or kidney disease, as well as those with a history of interstitial lung disease.

9. Storage: Store gefitinib tablets according to manufacturer instructions, typically at controlled room temperature and protected from light and moisture.

10. Patient Monitoring: Regular monitoring of liver function tests, renal function, and signs of interstitial lung disease is necessary during treatment.

11. Education: Patients should be educated on the purpose of the medication, potential side effects, and the importance of adherence to the prescribed dosage regimen.

12. Follow-Up: Close follow-up with healthcare providers is essential to monitor treatment response, manage side effects, and adjust the treatment plan as needed.